LSDI Fundamental Analysis - LUCY SCIENTIFIC DISCOVERY IN

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to LSDI. LSDI was compared to 195 industry peers in the Pharmaceuticals industry. While LSDI seems to be doing ok healthwise, there are quite some concerns on its profitability. LSDI does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year LSDI has reported negative net income.

LSDI had a negative operating cash flow in the past year.

1.2 Ratios

LSDI has a worse Return On Assets (-263.59%) than 93.26% of its industry peers.

The Return On Equity of LSDI (-13916.75%) is worse than 87.05% of its industry peers.

		Industry Rank	Sector Rank
ROA	-263.59%
ROE	-13916.75%
ROIC	N/A

ROA(3y)-104.64%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LSDI has a Gross Margin of 14.97%. This is comparable to the rest of the industry: LSDI outperforms 49.22% of its industry peers.

LSDI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	14.97%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LSDI does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for LSDI has been increased compared to 1 year ago.

LSDI has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -21.67, we must say that LSDI is in the distress zone and has some risk of bankruptcy.

LSDI has a worse Altman-Z score (-21.67) than 86.01% of its industry peers.

There is no outstanding debt for LSDI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-21.67

ROIC/WACCN/A

WACC7.34%

2.3 Liquidity

A Current Ratio of 0.38 indicates that LSDI may have some problems paying its short term obligations.

With a Current ratio value of 0.38, LSDI is not doing good in the industry: 95.85% of the companies in the same industry are doing better.

A Quick Ratio of 0.38 indicates that LSDI may have some problems paying its short term obligations.

With a Quick ratio value of 0.38, LSDI is not doing good in the industry: 94.82% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.38
Quick Ratio	0.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for LSDI have decreased strongly by -96.67% in the last year.

EPS 1Y (TTM)-96.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-66.29%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 23.49% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y78.1%

EPS Next 2Y34.54%

EPS Next 3Y23.49%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LSDI. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LSDI. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as LSDI's earnings are expected to grow with 23.49% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y34.54%

EPS Next 3Y23.49%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for LSDI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LUCY SCIENTIFIC DISCOVERY IN

NASDAQ:LSDI (6/28/2024, 8:12:35 PM)

After market: 0.4552 -0.06 (-11.42%)

0.5139

-0.16 (-23.29%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)02-13 2024-02-13/amc

Earnings (Next)N/A N/A

Inst Owners7.28%

Inst Owner Change0%

Ins Owners65.53%

Ins Owner Change0%

Market Cap904.46K

Analysts82.86

Price Target35.7 (6846.88%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-211.71%

Min EPS beat(2)-357.52%

Max EPS beat(2)-65.91%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-98.27%

Min Revenue beat(2)-100%

Max Revenue beat(2)-96.54%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	54.16
P/FCF	N/A
P/OCF	N/A
P/B	11.14
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-7.2

EYN/A

EPS(NY)-1.33

Fwd EYN/A

FCF(TTM)-3.61

FCFYN/A

OCF(TTM)-3.37

OCFYN/A

SpS0.01

BVpS0.05

TBVpS-0.78

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-263.59%
ROE	-13916.75%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	14.97%
FCFM	N/A

ROA(3y)-104.64%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.38
Quick Ratio	0.38
Altman-Z	-21.67

F-Score5

WACC7.34%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-96.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-66.29%

EPS Next Y78.1%

EPS Next 2Y34.54%

EPS Next 3Y23.49%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-66.17%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3Y23.21%

EBIT Next 5YN/A

FCF growth 1Y-136.42%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-123.44%

OCF growth 3YN/A

OCF growth 5YN/A

LUCY SCIENTIFIC DISCOVERY IN (LSDI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens